235 related articles for article (PubMed ID: 6733002)
21. Salivary phenytoin concentrations in epilepsy and in chronic renal failure.
Reynolds F; Ziroyanis PN; Jones NF; Smith SE
Lancet; 1976 Aug; 2(7982):384-6. PubMed ID: 73850
[TBL] [Abstract][Full Text] [Related]
22. Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay.
Cook CE; Amerson E; Poole WK; Lesser P; O'Tuama L
Clin Pharmacol Ther; 1975 Dec; 18(6):742-7. PubMed ID: 1204279
[TBL] [Abstract][Full Text] [Related]
23. In vivo binding characteristics of phenytoin to serum proteins in monotherapy pediatric patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Itokazu N; Sugimoto T
Int J Clin Pharmacol Ther; 2000 Jan; 38(1):25-9. PubMed ID: 10667833
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of phenytoin in epileptic children: value of the single morning sample.
Naglo AS; Nergårdh A; Boréus LO
J Neurol; 1990 Jun; 237(3):186-90. PubMed ID: 2370566
[TBL] [Abstract][Full Text] [Related]
25. Use of plasma unbound drug concentrations in adjusting phenytoin doses.
Bachmann K; Voeller K; Forney R
Ther Drug Monit; 1984; 6(2):173-8. PubMed ID: 6740736
[TBL] [Abstract][Full Text] [Related]
26. Is free fraction measurement of phenytoin always necessary in pediatric epileptic patients?
Johno I; Kuzuya T; Suzuki K; Hasegawa M; Nakamura T; Kitazawa S; Aso K; Watanabe K
Ther Drug Monit; 1988; 10(1):39-44. PubMed ID: 3376180
[TBL] [Abstract][Full Text] [Related]
27. Plasma albumin concentration and diphenylhydantoin binding in man.
Porter RJ; Layzer RB
Arch Neurol; 1975 May; 32(5):298-303. PubMed ID: 237499
[TBL] [Abstract][Full Text] [Related]
28. Measurement of phenytoin and carbamazepine in an ultrafiltrate of saliva.
Schramm W; Annesley TM; Siegel GJ; Sackellares JC; Smith RH
Ther Drug Monit; 1991 Sep; 13(5):452-60. PubMed ID: 1957339
[TBL] [Abstract][Full Text] [Related]
29. Nomogram for the prediction of unbound phenytoin concentrations in patients on a combined treatment of phenytoin and valproic acid.
May TW; Rambeck B; Nothbaum N
Eur Neurol; 1991; 31(1):57-60. PubMed ID: 2015840
[TBL] [Abstract][Full Text] [Related]
30. In vivo binding characteristics of phenytoin to serum proteins in monotherapy for adults with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Am J Ther; 2000 Nov; 7(6):359-63. PubMed ID: 11304643
[TBL] [Abstract][Full Text] [Related]
31. Importance of unbound phenytoin serum levels in head trauma patients.
Bauer LA; Edwards WA; Dellinger EP; Raisys VA; Brennan C
J Trauma; 1983 Dec; 23(12):1058-60. PubMed ID: 6418891
[TBL] [Abstract][Full Text] [Related]
32. Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury.
Markowsky SJ; Skaar DJ; Christie JM; Eyer SD; Ehresman DJ
Ann Pharmacother; 1996 May; 30(5):443-8. PubMed ID: 8740320
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy.
Lenn NJ; Robertson M
Neurology; 1992 May; 42(5):988-90. PubMed ID: 1579255
[TBL] [Abstract][Full Text] [Related]
34. Effect of temperature on binding characteristics of phenytoin to serum proteins in monotherapy adult patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Am J Ther; 2000 Jan; 7(1):11-5. PubMed ID: 11319568
[TBL] [Abstract][Full Text] [Related]
35. Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.
Lund L; Berlin A; Lunde KM
Clin Pharmacol Ther; 1972; 13(2):196-200. PubMed ID: 5017373
[No Abstract] [Full Text] [Related]
36. Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations.
Krasowski MD; Penrod LE
BMC Med Inform Decis Mak; 2012 Feb; 12():7. PubMed ID: 22333264
[TBL] [Abstract][Full Text] [Related]
37. No gender effect on binding characteristics of phenytoin to serum proteins in monotherapy for adult patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Am J Ther; 2000 Sep; 7(5):285-9. PubMed ID: 11317172
[TBL] [Abstract][Full Text] [Related]
38. Plasma concentrations of unbound valproate and the management of epilepsy.
Kilpatrick CJ; Bury RW; Fullinfaw RO; Moulds RF
Aust N Z J Med; 1987 Dec; 17(6):574-9. PubMed ID: 3128970
[TBL] [Abstract][Full Text] [Related]
39. Predictability of unbound antiepileptic drug concentrations in children treated with valproic acid and phenytoin.
Miles MV; Snead OC; Thorn MD
Clin Pharm; 1988 Sep; 7(9):688-93. PubMed ID: 3149223
[No Abstract] [Full Text] [Related]
40. Comparison of the Amicon Centrifree micropartition system with the Sartorius SM 13249E Centrisart I device to determine protein free phenytoin concentrations.
Zysset T; Zeugin T
Ther Drug Monit; 1986; 8(3):346-51. PubMed ID: 3529518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
